Clinical Trial Update: Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 [NA]

View source ↗

Summary

A completed clinical trial evaluating the BRAF inhibitor GSK2118436 (dabrafenib) for re-differentiation of radioiodine-refractory BRAF V600E-mutant papillary th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Thyroid Carcinoma

Drugs mentioned

• GSK2118436 (dabrafenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Papillary Thyroid Carcinoma | NA | Status: COMPLETED | Results posted: 2017-03-15